PLoS ONE (Jan 2021)

Validation of an admission coagulation panel for risk stratification of COVID-19 patients.

  • Darwish Alabyad,
  • Srikant Rangaraju,
  • Michael Liu,
  • Rajeel Imran,
  • Christine L Kempton,
  • Milad Sharifpour,
  • Sara C Auld,
  • Manila Gaddh,
  • Roman Sniecinski,
  • Cheryl L Maier,
  • Jeannette Guarner,
  • Alexander Duncan,
  • Fadi Nahab

DOI
https://doi.org/10.1371/journal.pone.0248230
Journal volume & issue
Vol. 16, no. 3
p. e0248230

Abstract

Read online

BackgroundThere is limited data on the markers of coagulation and hemostatic activation (MOCHA) profile in Coronavirus disease 2019 (COVID-19) and its ability to identify COVID-19 patients at risk for thrombotic events and other complications.MethodsHospitalized patients with confirmed SARS-COV-2 from four Atlanta hospitals were included in this observational cohort study and underwent admission testing of MOCHA parameters (plasma d-dimer, prothrombin fragment 1.2, thrombin-antithrombin complex, fibrin monomer). Clinical outcomes included deep vein thrombosis, pulmonary embolism, myocardial infarction, ischemic stroke, access line thrombosis, ICU admission, intubation and mortality.Main resultsOf 276 patients (mean age 59 ± 6.4 years, 47% female, 62% African American), 45 (16%) had a thrombotic endpoint. Each MOCHA parameter was independently associated with a thrombotic event (pConclusionsAn admission MOCHA profile is useful to risk-stratify COVID-19 patients for thrombotic complications and more effective than isolated d-dimer for predicting risk of ICU admission and intubation.